Zelluna Immunotherapy

Zelluna Immunotherapy's mission is to eliminate solid cancers by pioneering TCR-guided NK cell therapies. The company achieved a pivotal transformation in March 2025 by merging with Ultimovacs ASA, securing a public listing (OSE: ZLNA) and an infusion of capital to refocus entirely on its proprietary TCR-NK platform. Its strategy centers on developing scalable, allogeneic 'off-the-shelf' cell therapies that aim to combine precise tumor targeting with a favorable safety profile to address the vast, underserved solid tumor market.

Proprietary T cell receptor-guided natural killer (TCR-NK) cell therapy platform, combining the precise intracellular targeting of engineered TCRs with the potent effector functions and favorable safety profile of allogeneic NK cells to create 'off-the-shelf' therapies for solid cancers.

Zelluna competes in the crowded allogeneic cell therapy space but is differentiated by its focus on TCR engineering in NK cells. It faces competition from allogeneic CAR-T/NK companies (e.g., Allogene, Nkarta) and TCR-focused firms (e.g., Adaptimmune, Immunocore), but few are pursuing the specific TCR-NK combination, offering a potential first-mover advantage in this niche.